Algorae Pharmaceuticals Ltd AI Platform Validated With 2.5x Synergy Lift [VIDEO]
Algorae Pharmaceuticals AlgoraeOS v2 validation by Peter MacCallum Cancer Centre confirms the upgraded AI platform identifies synergistic drug combinations at 2.5 times the rate of its predecessor, with a 9-million-prediction multi-anchor pipeline now underway.
Key Takeaways
- Independent validation by the Victorian Centre for Functional Genomics at Peter MacCallum Cancer Centre confirmed AlgoraeOS v2 identifies synergistic drug combinations at approximately 2.5 times the rate of the earlier AOS1 model across 96 CBD-drug-cell line assessments.
- This is the second independent validation supporting the AlgoraeOS platform, with consistent results across both programs strengthening confidence in the predictive accuracy of the core discovery engine.
- The newly initiated multi-anchor pipeline spans 18 additional anchor drugs, over 9 million in silico predictions, and more than 6,000 flagged synergistic combinations — a substantial scale-up from the CBD-focused program.
- A $49,109 non-dilutive grant voucher from the Phenomics Australia Pipeline Accelerator scheme, awarded to 13 of 28 applicants, will co-fund the next VCFG validation collaboration.
- Several promising combinations from both validation programs are now under intellectual property review, with further preclinical assessment to determine which candidates advance.
![Genetic Signatures Ltd Gets BCAL Backing Through 10.2% Stake Purchase [VIDEO]](https://media.stockwirex.com/veo32Fnanobanana2Fb377bf6c-56e4-43e5-9dd1-8e08cd86e8c82Fimage_0.jpg)
![Algorae Pharmaceuticals Ltd Clarifies NSW Health Supply Panel Terms [VIDEO]](https://media.stockwirex.com/veo32Fnanobanana2Fbad3a004-c24a-4185-95c9-6312cede3da92Fimage_0.jpg)
![Imugene Ltd Reports Second Complete Response in BTKi Cohort [VIDEO]](https://media.stockwirex.com/veo32Fnanobanana2F352176a6-56e8-4d9b-a769-8060d34f35502Fimage_0.jpg)
Breaking ASX Alerts Direct to Your Inbox
Join +20,000 subscribers receiving alerts.
Join thousands of investors who rely on StockWire X for timely, accurate market intelligence.
- Breaking ASX announcements delivered within minutes
- Alerts delivered with expert analysis
- Optional text alert for subscribers
- No spam policy, unsubscribe any time
About the Publisher
StockWire X delivers fast, reliable, and actionable insights into significant developments across global markets, with coverage spanning technology, biotechnology, healthcare, financials, and emerging industries. Our mission is to provide clear, data-driven content that empowers investors to identify opportunities and make informed decisions ahead of the market.
Our network spans key financial and investment hubs worldwide, ensuring subscribers receive timely updates on market-moving announcements, news, macroeconomic trends, and corporate developments.
Use of Technology
We harness advanced technologies to enhance the speed, accuracy, and relevance of our reporting.
While technology accelerates our workflow, every piece of content is selected, validated, and published by human professionals, in accordance with best practices for accuracy, transparency, and investor value. This hybrid approach ensures speed without compromising editorial integrity.
Feedback and Accuracy
We are committed to accuracy and fairness in our reporting. If you believe any information we have published is inaccurate, incomplete, or misleading, please contact us at admin@stockwirex.com so we can review and address the matter promptly.
Disclaimer
StockWire X provides readers with access to market news, educational content, and commentary from financial services professionals, industry experts, and companies (“Contributors”).
StockWire X does not hold an Australian Financial Services Licence (AFSL) and relies on the exemption available under section 911A(2)(eb) of the Corporations Act 2001 (Cth) in respect of any financial product advice provided.
Any advice or information published by StockWire X is general in nature only and has been prepared without taking into account your personal objectives, financial situation, or needs. Before acting on any information, you should consider whether it is appropriate for your circumstances and seek independent, licensed financial advice. You should also obtain and read any relevant Product Disclosure Statement (PDS) or other offer document before making an investment decision.
StockWire X makes no guarantee as to the accuracy, completeness, or timeliness of the information provided, and accepts no responsibility for any loss arising from reliance on it. All content is published in good faith for informational purposes only.
Disclosure
StockWire X may have commercial relationships with some contributors or companies mentioned in our content. Any such relationships will be disclosed where relevant.
If you believe any information we have published is inaccurate, incomplete, or misleading, please contact us at admin@stockwirex.com so we can review and address the matter promptly.